QURE · uniQure N.V.

Current Thesis

uniQure’s AMT-130 regulatory recovery needs FDA filing acceptance with priority review and a weekly close above the June offering price of $45.50; a weekly close below $40.25 would invalidate the market recovery thesis. The company submitted its Huntington’s disease biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) on 2026-09-02. Acceptance and priority review remain separate from submission. Company announcement, 2026-09-02.

The narrative is maturing — the filing milestone is complete, while the 2026-09-18 adjusted close of $44.00 remains below the June offering price. The supplied market series records a three-month price decline of 0.9% and a 14-day relative strength index (RSI) of 30.1 on that date. These measurements support a weak-momentum interpretation; they do not establish selling pressure from any particular investor group.

Bullish and bearish views on uniQure N.V.

The model's bull view on uniQure N.V. (QURE), in brief: Submission removes a scheduling risk. The 2026-09-02 announcement confirms both U.S. and UK applications were submitted. The remaining regulatory test is acceptance, rather than delivery of the application. Company announcement. Funding extends beyond the filing. uniQure… The bear view: Durability remains incompletely established. Both cases follow in full.

Bull Case

• Submission removes a scheduling risk. The 2026-09-02 announcement confirms both U.S. and UK applications were submitted. The remaining regulatory test is acceptance, rather than delivery of the application. Company announcement.
• Funding extends beyond the filing. uniQure reported $810.3 million in cash, cash equivalents and current investment securities at 2026-06-30. Management projected funding into 2030; an officially shortened runway would invalidate that financing assumption. 2026-07-29 results.

Bear Case

• Durability remains incompletely established. The 2026-07-29 update described four-year follow-up covering 24 patients, with 12 in each dose group. That sample is too small to establish broad durability or exclude uncommon harms. Company update.
• The comparison remains externally controlled. The 2026-09-02 submission announcement identifies a matched natural-history comparison for the supporting analysis. Filing acceptance would not itself resolve the clinical uncertainty inherent in that comparison. Company announcement.
• Quarterly results.

Setup & Price Structure

The 2026-09-18 adjusted close was $44.00, with the shares 37.7% below the supplied 52-week high of $70.59. The low RSI does not establish a reversal. A weekly close above the $45.50 June offering price is the specified recovery condition; the 2026-07-17 public close of $40.25 supplies the lower reference for invalidation. No current moving-average value is available to support a moving-average claim.

Issuance is the concrete supply observation: the 2026-07-29 results report June gross proceeds of $259 million, including the underwriters’ option, at $45.50 per share. That documents financing supply, not current holder intentions. Retail-flow, short-interest and ownership-concentration measurements are unavailable, so crowding cannot be established. Quarterly results.

Catalyst Calendar (next 30 days)

• ~2026-09-30, estimated window endpoint: Four-year AMT-130 data were promised before the end of the third quarter in the 2026-09-02 announcement. This is a deadline marker, not an announced presentation date; no release by that endpoint would constitute a missed timing commitment. Company announcement.
• ~2026-11-01, estimated, beyond 30 days: The filing determination remains the later event on which the regulatory thesis turns. The 2026-09-02 release specifies a 60-day filing review and says priority review, if granted, would provide a subsequent six-month review cycle. The calendar date is unconfirmed. Company announcement.

What Would Change Our Mind

Loss of the July price reference would break the market recovery case: a weekly close below $40.25, the public close recorded on 2026-07-17, is the explicit invalidation condition. This replaces the earlier $34 threshold with a nearer, dated market reference; no current moving-average support is asserted.

The positive case is defined as FDA filing acceptance with priority review and a weekly close above the $45.50 June offering price before that invalidation occurs. A refusal to file or denial of priority review would independently defeat this specific expedited-review thesis. Favorable four-year observations would remain supporting evidence rather than proof of durable efficacy across the patient population.

Correlation Notes

The 2026-09-02 application makes this a single-company regulatory setup. The supplied evidence contains no paired return series supporting a measured relationship with biotechnology indices or other gene-therapy companies. Theme tags describe the disease and regulatory exposure; they do not establish a common market driver.